Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) EBT (2017 - 2025)

Historic EBT for Organogenesis Holdings (ORGO) over the last 9 years, with Q3 2025 value amounting to $21.2 million.

  • Organogenesis Holdings' EBT rose 26338.66% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.2 million, marking a year-over-year increase of 5823.91%. This contributed to the annual value of -$2.8 million for FY2024, which is 12701.12% down from last year.
  • As of Q3 2025, Organogenesis Holdings' EBT stood at $21.2 million, which was up 26338.66% from -$11.8 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' EBT ranged from a high of $21.2 million in Q2 2021 and a low of -$25.8 million during Q1 2025
  • Its 5-year average for EBT is $3.9 million, with a median of $7.6 million in 2023.
  • Per our database at Business Quant, Organogenesis Holdings' EBT surged by 67087.97% in 2024 and then plummeted by 49366.8% in 2025.
  • Over the past 5 years, Organogenesis Holdings' EBT (Quarter) stood at $18.9 million in 2021, then crashed by 53.66% to $8.8 million in 2022, then tumbled by 120.52% to -$1.8 million in 2023, then soared by 670.88% to $10.3 million in 2024, then surged by 106.38% to $21.2 million in 2025.
  • Its EBT was $21.2 million in Q3 2025, compared to -$11.8 million in Q2 2025 and -$25.8 million in Q1 2025.